HomeNewsRegulation

Health Ministry Notifies Stricter Drug Rules against Fake Data

Health Ministry Notifies Stricter Drug Rules against Fake Data

The Union Ministry of Health and Family Welfare has notified amendments to the Drugs Rules, 1945 through G.S.R number 756 (E), dated October 16, 2025.

In addition to existing enforcement provisions under the Drugs and Cosmetics Act, 1940, these newly notified provisions empower the Licensing Authority to debar further applications by entities who submit fake or fabricated data in support of their applications. This will apply to all applications filed under various provisions of the Drugs Rules 1945.

Currently, an applicant submitting fabricated data faces enforcement actions such as rejection of applications and/or cancellation of existing licenses. With this amendment, they would be debarred from filing further applications with the concerned regulatory authority, either State or the Centre (as applicable) for a specified period of time. A due process has been prescribed through the issuance of a show-cause notice before any such punitive action is taken. There is also a provision for appeal provided.

Sound scientific data submitted by applicants forms the basis for regulatory evaluation of the quality, safety and efficacy of drugs. Submission of fake or fabricated data compromises the integrity of the regulatory process, casts aspersions over the quality of drugs and may pose serious risks to public health. The present amendment is intended to deter such misconduct, strengthen accountability among applicants and ensure that approvals of drugs are backed by reliable and scientifically valid evidence.

The notification is in line with the government's efforts to strengthen India's regulatory framework in accordance with global best practices. It aims to promote those drugs manufacturers and distributors who are compliant with regulatory framework of the country and endeavors to deal with any reported instances of malpractice. It complements the ongoing regulatory reform in the pharmaceutical domain with renewed focus on enhancing oversight, promoting ethical practices and ensuring that unscrupulous entities are adequately penalised.

More news about: regulation | Published by News Bureau | August - 07 - 2026

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members